A detailed history of Premier Path Wealth Partners, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Premier Path Wealth Partners, LLC holds 4,255 shares of GILD stock, worth $381,928. This represents 0.06% of its overall portfolio holdings.

Number of Shares
4,255
Previous 3,329 27.82%
Holding current value
$381,928
Previous $228 Million 56.18%
% of portfolio
0.06%
Previous 0.04%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024

BUY
$66.59 - $83.99 $61,662 - $77,774
926 Added 27.82%
4,255 $357 Million
Q2 2024

Jul 24, 2024

SELL
$63.15 - $72.88 $37,763 - $43,582
-598 Reduced 15.23%
3,329 $228 Million
Q1 2024

Apr 24, 2024

SELL
$71.58 - $87.29 $71,222 - $86,853
-995 Reduced 20.22%
3,927 $288 Million
Q4 2023

Jan 12, 2024

BUY
$73.27 - $83.09 $360,634 - $408,968
4,922 New
4,922 $399 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $113B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Premier Path Wealth Partners, LLC Portfolio

Follow Premier Path Wealth Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Premier Path Wealth Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Premier Path Wealth Partners, LLC with notifications on news.